Thrombotic microangiopathy
MONDO:0019737The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
154 clinical trials for this condition and its sub-types, 26 tagged with Thrombotic microangiopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thrombotic microangiopathy
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Atypical hemolytic-uremic syndrome 19 trials
4 sub-types
Most studied deeper sub-types
-
New drug aimed at saving lives after stem cell transplants
Disease control Recruiting nowThis study tests a drug called iptacopan in 30 people who have a serious blood vessel problem after a stem cell transplant. The drug aims to block a part of the immune system that damages blood vessels. Researchers will check if it helps patients live longer and recover organ fun…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Drug could double survival in rare stem cell transplant complication
Disease control Recruiting nowThis trial tests the drug eculizumab in adults who develop a severe blood clotting disorder called high-risk transplant-associated thrombotic microangiopathy (TA-TMA) after a stem cell transplant. The condition can cause multiple organ failure and has a poor outlook. The study ai…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for aHUS patients: Long-Term iptacopan study launches
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug iptacopan in people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS). Participants must have completed a previous iptacopan study and still benefit from the drug. The goal is to moni…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a simple pill replace infusions for aHUS patients?
Disease control Recruiting nowThis study is for adults with a rare blood disorder called aHUS who are currently receiving antibody infusions. Researchers want to see if switching to a daily pill called iptacopan is safe and works just as well to prevent dangerous blood clots. About 50 participants will take i…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment
Disease control Recruiting nowThis study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …
Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Blood test could unlock precision medicine for deadly TMA
Diagnosis Recruiting nowThis study is testing a new blood test (the HMEC test) to see if it can better identify which patients with thrombotic microangiopathy (TMA) have a specific immune system problem driving their disease. TMA is a severe condition that damages kidneys and the brain. The researchers …
Sponsor: Maastricht University Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New study aims to detect lung damage earlier in young transplant patients
Knowledge-focused Recruiting nowThis study follows 2,000 children who receive stem cell transplants to better understand and detect lung injuries that can occur after the procedure. Researchers will track participants for two years, collecting samples and health data to find ways to diagnose problems earlier. T…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hormone Therapy's hidden effects: new study eyes metabolism and heart risks
Knowledge-focused Recruiting nowThis study observes 80 transgender individuals starting cross-sex hormone therapy (testosterone or estrogen) to see how it changes eating behavior, metabolism, weight, and heart health. Participants are followed over time with no extra treatments or procedures. The goal is to und…
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Massive study aims to unlock secrets of rare blood disorder
Knowledge-focused Recruiting nowThis study reviews medical records from over 1,200 people with immune thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. The goal is to understand long-term health problems, such as heart disease and thinking issues, that survivors face. By an…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Massive global registry tracks Real-World outcomes for rare kidney disease
Knowledge-focused Recruiting nowThis observational study follows 3,000 people with atypical hemolytic-uremic syndrome (aHUS), a rare and serious kidney condition. Researchers will collect safety and effectiveness data on patients treated with eculizumab or ravulizumab, as well as those receiving other care. The…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:43 UTC